Navigation Links
TREVENTIS Corporation Founder Wins Prestigious Discovery Award

PHILADELPHIA and Nova Scotia, CANADA, Jan. 11, 2011 /PRNewswire/ -- TREVENTIS Corporation founder, Christopher Barden, Ph.D., was awarded "Emerging Professional Award" for his work in computer-aided drug design.  Dr. Barden received the Award at the 8th annual Discovery Awards dinner sponsored by Nova Scotia's Discovery Centre.  His work has provided TREVENTIS with a proprietary drug discovery system called the Common Conformational Motif (CCM).  

In addition, Company founder Sultan Darvesh, M.D., Ph.D., was one of only three finalists in the category of "Professional of Distinction" for his work and recognized expertise in the field of butyrylcholinesterase (BuChE) as a diagnostic and therapeutic target in diseases of the brain.  Dr. Darvesh heads the Company's efforts in developing a diagnostic test for Alzheimer's disease.  

Finalists and award winners are recognized by the Discovery Centre as the top science practitioners in Nova Scotia.  Three finalists are selected among all of Nova Scotia's scientific professionals in both the regular Professional and early-career Emerging categories.  The Discovery Awards "recognize the talented individuals...whose exemplary work in science and technology inspire us all," according to its web site (  Past recipients of the Discovery Award include TREVENTIS founder Donald Weaver, M.D., Ph.D., a neurologist and recognized expert in Alzheimer's disease.

"We are delighted to have the scientific foundation of the Company validated by this prestigious award," said Bill McIntosh, CEO of TREVENTIS Corporation.  "That they were nominated for these awards is clear recognition of the significant work they are doing for the Company and for science."

Dr. Barden is part of a team of TREVENTIS chemists and biologists who have discovered and synthesized multiple classes of therapeutic compounds that block the aggregation of misfolding proteins.  Misfolding proteins have been implicated in numerous CNS diseases including Parkinson's disease and Alzheimer's disease, the Company's current focus.  

About TREVENTIS Corporation

TREVENTIS Corporation, headquartered in Southeastern Pennsylvania, has research operations in Halifax, Nova Scotia, Canada.  The company is focused on the discovery and early stage development of disease-modifying, small molecule drugs for Alzheimer's and other protein misfolding diseases such as Parkinson's and Huntington's disease.  In addition to its therapeutics programs, TREVENTIS has a novel approach to the development of diagnostics for early diagnosis as well as monitoring treatment effects in Alzheimer's disease, MS and primary brain tumors.For more information contact:

L. William McIntosh, CEOTREVENTIS Corporationwww.TREVENTIS. and wmcintosh@treventis.com610-488-6081  

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Saints Medical Center and ZOLL Medical Corporation Enter Collaborative Agreement
2. Luminex Corporation to Present at JP Morgan Healthcare Conference
3. SRI International Completes Integration of Sarnoff Corporation
4. Heska Corporation Announces Stockholder Approval of Reverse Split
5. Pfizer Animal Health to Acquire Synbiotics Corporation, Entering Diagnostics Sector
6. Webcast Alert: Heska Corporations Special Meeting of Stockholders Webcast
7. LodgeNet Healthcare, MDM Healthcare and Child Health Corporation of America Reach Agreement
8. VIDEO from Siemens Corporation Available on Amazing Medical Images: Diagnosing in the Digital Age
9. Heska Corporation Awards $25,000 Grand Prize to Pets Forever
10. Unilife Corporation Moves into New State-of-the-Art Manufacturing Facility and Global Headquarters
11. Oxford Finance Corporation Hires Debbie Baker to Support Life Science Business Development in Western North America
Post Your Comments:
(Date:11/24/2015)... , November 25, 2015 The ... to repeated failure of IVF cycles. After failure of ... dejected and had lost all hopes that she would be able to ... miracle child conceived after failure of over 15 IVF ... (UK) before they decided to take one last attempt with Gaudium ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ... NASDAQ: EPIX ) announced today that the first ... study of EPI-506 as a treatment for metastatic castration-resistant ... and Canada.  --> ... --> In the Phase 1/2 clinical trial, ESSA ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Today, Mothers Against Drunk ... roadways has dropped below 10,000 for the first time since 2011. In 2014, there ... According to data released by the National Highway Traffic Safety Administration (NHTSA), 32,675 people ...
(Date:11/25/2015)... ... ... An unlikely combination of recycled plastic shopping bags in ... to have a more dignified and comfortable night’s sleep. , Residents of Friendship ... bags into sleeping mats for the homeless. The project, according to Jeannette ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... bunion treatment, is offering lower prices in an early celebration of the early ... the promotional price of $29.95 each (normally $33.95 ea). Black Friday promotional pricing ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a wide variety ... Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in Tucson, AZ ... the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the patient during ...
(Date:11/24/2015)... ... , ... DMG Productions announced that they will feature Aphria, Inc., in an ... Channel. Dates and show times TBA. , Aphria, Inc., is a publicly traded company ... and supplying medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). ...
Breaking Medicine News(10 mins):